Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply

Aliment Pharmacol Ther. 2020 Aug;52(3):563-564. doi: 10.1111/apt.15888.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized
  • Child
  • Cohort Studies
  • Crohn Disease*
  • Humans
  • Inflammatory Bowel Diseases*
  • Tumor Necrosis Factor-alpha
  • Ustekinumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • vedolizumab
  • Ustekinumab